Oslo, Norway, 05 February 2019 – PCI Biotech invites to a presentation of the company’s fourth quarter and preliminary 2018 report on Wednesday 13 February 2019 at Oslo Cancer Cluster Innovation Park.
Time: Wednesday February 13, 08:30am – 09:30am CET (local time).
Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo.
The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to email@example.com.
The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console.
The interim report and the presentation will be available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com from 07:30am (CET) on 13 February 2019.
For further information, please contact:
Ronny Skuggedal, CFO
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme has a Phase I study ongoing and preparations underway for a pivotal study with the potential of accelerated / conditional marketing approval as a first-line treatment given the rare disease status and high unmet medical need for bile duct cancer. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising Field.
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Ronny Skuggedal, CFO, firstname.lastname@example.org, Mobile: +47 9400 5757